Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies

Next Previous
Trial Profile

A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LYL 845 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Lyell Immunopharma

Most Recent Events

  • 06 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 28 Feb 2024 According to a Lyell Immunopharma media release, Epi-R P2 is expected to be incorporated into the Phase 1 trial of LYL845 in 2024.
  • 28 Feb 2024 According to a Lyell Immunopharma media release, Initial clinical and translational data from the Phase 1 trial of LYL845 are expected in the second half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top